AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 157 filers reported holding AKERO THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,092,803 | -23.4% | 337,936 | -29.3% | 5.18% | -24.9% |
| Q2 2023 | $22,308,778 | +187.9% | 477,857 | +135.9% | 6.90% | +115.7% |
| Q1 2023 | $7,749,984 | -70.0% | 202,561 | -57.1% | 3.20% | -56.8% |
| Q4 2022 | $25,871,080 | +153.3% | 472,100 | +57.4% | 7.40% | +114.2% |
| Q3 2022 | $10,215,000 | +315.2% | 300,000 | +15.2% | 3.46% | +356.4% |
| Q2 2022 | $2,460,000 | +200.4% | 260,325 | +688.2% | 0.76% | +107.4% |
| Q2 2021 | $819,000 | -11.7% | 33,028 | +3.2% | 0.36% | -27.9% |
| Q1 2021 | $928,000 | +2.2% | 32,000 | -9.0% | 0.51% | -4.2% |
| Q4 2020 | $908,000 | – | 35,179 | – | 0.53% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $179,512,000 | 24.20% |
| venBio Partners LLC | 2,444,311 | $75,260,000 | 11.44% |
| Versant Venture Management, LLC | 777,727 | $23,946,000 | 4.38% |
| Redmile Group, LLC | 2,336,357 | $71,936,000 | 1.32% |
| Vivo Capital, LLC | 571,833 | $17,607,000 | 1.02% |
| Cormorant Asset Management, LP | 859,550 | $26,466,000 | 1.02% |
| Boxer Capital, LLC | 831,495 | $25,602,000 | 0.88% |
| Integral Health Asset Management, LLC | 85,000 | $2,617,000 | 0.80% |
| EAM Global Investors LLC | 49,718 | $1,531,000 | 0.56% |
| Crawford Lake Capital Management, LLC | 43,826 | $1,349,000 | 0.56% |